CSIMarket
 


Cytomx Therapeutics Inc   (CTMX)
Other Ticker:  
 

Cumulative Cytomx Therapeutics Inc 's Quick Ratio for Trailing Twelve Months Period

CTMX's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

CTMX Quick Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth 50.03 % 42.17 % 47.19 % 95.98 % -1.94 %
Y / Y Cash & cash equivalent Growth -0.09 % -20.73 % -22.1 % -36.56 % -17.77 %
Quick Ratio for Trailing Twelve Months Period 1.31 1.42 1.64 1.94 2.62
Total Ranking # 1201 # 1255 # 1289 # 1384 # 1183
Seq. Current Liabilities Growth 3.83 % -6.54 % -0.88 % 55.98 % -1.61 %
Seq. Cash & cash equivalent Growth 7.33 % -11.56 % 5.6 % -0.33 % -14.85 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to rise in Current Liabilities in the III. Quarter to $147 millions, average cumulative Quick Ratio for Trailing Twelve Months Period decreased to 1.31 below Cytomx Therapeutics Inc average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 351 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Cytomx Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about CTMX
Quick Ratio CTMX in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 352
Sector # 642
S&P 500 # 1191


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
5.46 3.61 1.31
(Jun 30 2017)   (Sep 30 2023)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick Ratio for Trailing Twelve Months Period
Calithera Biosciences Inc   3.58 
Inmed Pharmaceuticals Inc   3.58 
Vertex Pharmaceuticals Inc  3.55 
Harmony Biosciences Holdings inc   3.50 
Pharming Group N v   3.47 
Edesa Biotech Inc   3.42 
Enveric Biosciences Inc   3.40 
Nextcure Inc   3.38 
Elicio Therapeutics Inc   3.36 
Azitra Inc   3.35 
G1 Therapeutics Inc   3.33 
Arcturus Therapeutics Holdings Inc   3.32 
Axsome Therapeutics Inc   3.32 
Adc Therapeutics Sa  3.30 
Neximmune Inc   3.29 
Geron Corp  3.28 
China Health Industries Holdings Inc   3.26 
Akari Therapeutics Plc  3.24 
Tg Therapeutics Inc   3.24 
Vanda Pharmaceuticals Inc   3.23 
Can fite Biopharma Ltd   3.19 
Clene Inc   3.19 
Eyenovia inc   3.17 
Revelation Biosciences Inc   3.16 
Ocular Therapeutix Inc   3.13 
Regeneron Pharmaceuticals Inc   3.08 
Hookipa Pharma inc   3.07 
Maia Biotechnology Inc   3.06 
Provention Bio Inc   3.03 
Insmed Inc  2.90 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com